# Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia

> **NCT01968486** · PHASE1 · COMPLETED · sponsor: **University of Campania Luigi Vanvitelli** · enrollment: 60 (actual)

## Conditions studied

- Myopia, Degenerative

## Interventions

- **DRUG:** PDT standard fluence, ranibizumab
- **DRUG:** PDT reduced fluence, ranibizumab
- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT01968486
- **Lead sponsor:** University of Campania Luigi Vanvitelli
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01968486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01968486, "Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01968486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*